Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
14 mars 2023 16h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound
10 févr. 2023 07h35 HE
|
Sunshine Biopharma Inc.
MONTREAL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas...
Cell BioEngines Enters into an Exclusive Worldwide Agreement to Develop and Commercialize Potent Immune Cell States to Cure Cancer
25 janv. 2023 21h15 HE
|
Cell BioEngines, Inc.
BOSTON and NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines Inc. (the “Company”), a cell and gene therapy company focused on developing an allogenic cell-based product for solid tumors,...
BioNTech kündigt strategische Partnerschaft mit der Regierung des Vereinigten Königreichs an, um bis 2030 bis zu 10.000 Patientinnen und Patienten mit personalisierten mRNA-Krebsimmuntherapien zu behandeln
05 janv. 2023 19h01 HE
|
BioNTech SE
Die mehrjährige Vereinbarung fokussiert sich auf drei strategische Bereiche: Krebsimmuntherapien, Impfstoffe gegen Infektionskrankheiten und weitere Expansion von BioNTech im Vereinigten...
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
05 janv. 2023 19h01 HE
|
BioNTech SE
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech aims to design and roll out...
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
03 janv. 2023 07h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
15 déc. 2022 07h48 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
17 nov. 2022 06h59 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion CEO comments on strategic focus
10 nov. 2022 04h10 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion welcomes Per Norlén as new CEO.
05 oct. 2022 08h32 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...